HBIO Earnings Prediction
The chart below shows how HBIO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HBIO sees a +6.05% change in stock price 10 days leading up to the earnings, and a -3.73% change 10 days following the report. On the earnings day itself, the stock moves by +0.11%. This data can give you a slight idea of what to expect for the next quarter's release.
HBIO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
HBIO Earnings Analysis
Harvard Bioscience Inc Corporation (HBIO.O) Earnings Conference Call
Positive
Earnings Per Share Beat: Harvard Bioscience, Inc. reported an EPS of $0.06, beating expectations of $0.05.
Q4 Revenue Increase: Revenue in Q4 was $24.6 million, showing a 12% sequential increase from Q3.
Effective Cost Management: Adjusted operating income was $2.5 million, representing 10% of revenue, indicating effective cost management.
EBITDA Improvement in Q4: Adjusted EBITDA improved to $3 million in Q4, up from $1.3 million in Q3, reflecting revenue and margin growth.
Gross Margin Stability: Gross margin for Q4 was maintained at 57%, close to the target of 60%, despite lower revenue levels.
Positive Book-to-Bill Ratio: The company experienced a positive book-to-bill ratio, indicating strong order intake and future revenue potential.
Regional Revenue Stabilization: Sequential revenue growth was observed in the Americas (3%), Europe (28%), and Asia Pacific (8%), signaling stabilization in various markets.
Product Launch Success: The launch of new products, including the SoHo telemetry devices and VivaMARS neurobehavioral monitoring system, is generating strong interest and demand.
Electroporation System Adoption: The BTX electroporation system has been adopted by a top five pharma company, achieving a $1 million annual run rate in consumable revenue.
Market Interest in Organoid Platform: The MeshMEA organoid platform is gaining traction with early adopters like Stanford and the Mayo Clinic, indicating strong market interest.
Operating Expense Reduction: The company has successfully reduced operating expenses by $2 million or 12% year-over-year, positioning for improved profitability in 2025.
Negative
Q4 Revenue Decline: Revenue in Q4 2024 was $24.6 million, which is 13% lower than Q4 2023, indicating a decline in year-over-year performance.
Revenue Decline Analysis: Full year revenue decreased to $94 million from $112 million in the previous year, reflecting a significant drop in overall sales.
Breakeven Operating Income Challenges: Operating income was breakeven on a GAAP basis, which suggests challenges in maintaining profitability despite some cost reductions.
Decline in Adjusted EBITDA: Adjusted EBITDA for Q4 was $3 million, down from $3.6 million in Q4 2023, indicating a decline in operational efficiency year-over-year.
Cash Flow Decline: Cash flow from operations was $1.7 million in Q4, significantly lower than $4.3 million in the same quarter last year, highlighting cash flow challenges.
Net Leverage Ratio Concerns: The company was not in compliance with its net leverage ratio covenant at year-end, which raises concerns about financial stability and creditworthiness.
Revenue Dip Projection: The company expects a dip in revenue for Q1 2025, projecting between $19 million to $21 million, which reflects ongoing uncertainty in the market.
Audit and Refinancing Costs: The anticipated high professional fees related to audit and debt refinancing activities in Q1 2025 may negatively impact EBITDA, indicating potential financial strain.
HBIO FAQs
How does HBIO typically perform around its earnings report dates?
Is Harvard Bioscience Inc (HBIO) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
HBIO Earning Call Sentiment
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2024 Earnings Call Transcript
HBIO.O
2.24%Positive
The earnings call reveals several concerns: declining revenue, lower gross margins, debt compliance issues, and high professional fees. Although new products show growth, uncertainties around NIH funding and ERP challenges pose risks. Withholding full-year guidance further adds to investor uncertainty. Despite some cost reductions, the lack of a share repurchase program and the negative sentiment from analysts in the Q&A suggest a negative stock price reaction.
